ICER suggests Novartis' MS therapy siponimod won't be cost-effective

ICER said the price of multiple sclerosis therapy Mayzent siponimod from Novartis would have to reach a monthly net price of $995 to meet its standard cost-effectiveness threshold of $150,000

Read the full 303 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE